Stock analysts at Royal Bank of Canada began coverage on shares of V2X (NYSE:VVX – Get Rating) in a research note issued on Wednesday, The Fly reports. The firm set an “outperform” rating on the stock.
Separately, TheStreet cut V2X from a “b” rating to a “c” rating in a research report on Thursday, December 22nd.
V2X Stock Performance
Shares of VVX traded down $0.42 during midday trading on Wednesday, hitting $42.69. 15,231 shares of the stock traded hands, compared to its average volume of 49,777. The business’s 50 day moving average price is $40.77 and its two-hundred day moving average price is $37.93. The firm has a market capitalization of $1.30 billion, a PE ratio of 35.87 and a beta of 0.91. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.29 and a current ratio of 1.29. V2X has a 1-year low of $29.55 and a 1-year high of $47.79.
Hedge Funds Weigh In On V2X
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. North Star Investment Management Corp. acquired a new stake in shares of V2X in the fourth quarter valued at $753,000. Assenagon Asset Management S.A. acquired a new stake in V2X in the 4th quarter valued at about $718,000. Rothschild Investment Corp IL bought a new position in shares of V2X during the 4th quarter valued at about $376,000. Allspring Global Investments Holdings LLC acquired a new position in shares of V2X in the 4th quarter worth approximately $382,000. Finally, Unison Advisors LLC bought a new stake in shares of V2X in the 4th quarter worth approximately $453,000.
V2X Company Profile
V2X, Inc provides solutions and support to defense clients globally. It delivers integrated solutions across the operations and logistics, aerospace, training and technology markets to national security, defense, civilian and international clients. The company was founded on July 8, 2022 and is headquartered in Colorado Springs, CO.
- Get a free copy of the StockNews.com research report on V2X (VVX)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for V2X Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for V2X and related companies with MarketBeat.com's FREE daily email newsletter.